Centrus Energy shares have erased 69 percent of their value since peaking at $464.25 on October 16 last year, leaving the stock at roughly $143 even as the company's order book swells to $4.5 billion. The divergence underscores a market that is pricing execution risk far more aggressively than the headline backlog figure suggests.
The backlog is real but distant
By the close of the June quarter, Centrus held $4.5 billion in combined low-enriched and high-assay low-enriched uranium commitments, a pile equivalent to nine and a half times the revenue analysts project for the full year. The company is the sole U.S.-listed producer of HALEU, the fuel required for next-generation reactors, and one of only a handful licensed to sell commercial LEU. Yet most of those contracted pounds will not ship until the late 2020s and the 2030s, leaving a wide gap between booked orders and recognized sales.
Near-term estimates point the wrong way
Consensus forecasts show revenue slipping from $449 million this year to $443 million in 2028, with net income falling from $78 million to $50 million over the same span. The decline coincides with a domestic supply crunch: the United States will bar Russian uranium imports entirely by 2028, before Centrus can bring its Ohio enrichment cascade back to commercial scale. The timing mismatch forces the company to buy expensive spot material or forgo sales, pressuring margins just as capital expenditure ramps up for the restart.
Capital intensity meets expensive money
Restarting domestic enrichment is capital intensive, and rising borrowing costs make the debt required to fund it more costly. The stock still changes hands at roughly 50 times next year's estimated earnings, a multiple that assumes flawless execution on a multi-year construction timeline. For investors seeking nuclear exposure, the risk-reward favors diversified operators with existing cash flow over a single-asset turnaround priced for perfection.